Longeveron (LGVN) Net Margin (2020 - 2026)
Longeveron (LGVN) recorded quarterly Net Margin of 1199.75% in Q1 2026, up 19.56% quarter-over-quarter from 1491.51% in Q4 2025, and up 16009.0% on a YoY basis from N/an in Q1 2025.
Longeveron (LGVN) Net Margin (2020 - 2026) Analysis & Trends
Longeveron's Net Margin history runs 7 years deep, the most recent figure standing at 1199.75% for Q1 2026.
- In Q1 2026, Net Margin rose 16009.0% year-over-year to 1199.75%; the TTM figure through Mar 2026 stood at 1847.7% (down 69066.0% YoY), while the FY2025 annual figure was 1893.58%, down 86419.0% from the prior year.
- Net Margin was 1199.75% for Q1 2026 at Longeveron, up from 1491.51% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 590.94% in Q3 2024 to a low of 9568.25% in Q4 2023.
- Historically, Net Margin has averaged 2589.02% across 5 years, with a median of 1591.14% in 2025.
- The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 588478 bps in 2023, then soared 889147 bps in 2024.
- A 5-year view of Net Margin shows it stood at 3683.47% in 2022, then tumbled by 160 bps to 9568.25% in 2023, then surged by 93 bps to 676.78% in 2024, then slumped by 120 bps to 1491.51% in 2025, then increased by 20 bps to 1199.75% in 2026.
- The last three Net Margin figures came in at 1199.75% (Q1 2026), 1491.51% (Q4 2025), and 5270.8% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -1,199.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,199.75% |
| Dec 31, 2025 | -1,491.51% |
| Sep 30, 2025 | -5,270.80% |
| Jun 30, 2025 | -1,591.14% |
| Mar 31, 2025 | -1,359.84% |
| Dec 31, 2024 | -676.78% |
| Sep 30, 2024 | -590.94% |
| Jun 30, 2024 | -2,545.73% |
| Mar 31, 2024 | -746.35% |
| Dec 31, 2023 | -9,568.25% |
| Sep 30, 2023 | -3,936.00% |
| Jun 30, 2023 | -2,595.39% |
| Mar 31, 2023 | -1,690.32% |
| Dec 31, 2022 | -3,683.47% |
| Sep 30, 2022 | -5,244.00% |
| Jun 30, 2022 | -905.79% |
| Mar 31, 2022 | -917.30% |
| Dec 31, 2021 | -1,929.67% |
| Sep 30, 2021 | -2,114.66% |
| Jun 30, 2021 | -1,035.58% |